Advertisement Scil Proteins completes manufacturing deal with Lundbeck - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Scil Proteins completes manufacturing deal with Lundbeck

Scil Proteins, a biotech company specialized in the development and production of recombinant proteins, has completed a manufacturing agreement for Lundbeck.

Scil Proteins took up the process development and early stage GMP manufacturing for a recombinant protein candidate.

Scil Proteins CEO Ulrike Fiedler said the company is happy that Lundbeck selected their protein manufacturing competence and facilities to deliver their protein.

Scil Proteins manufactures Boehringer Mannheim and Roche developed protein Reteplase for the treatment of myocardial infarction.